title: [The radiosensitization of nimotuzumab on CAL-27 cells after125I seeds irradiation].
abstract: OBJECTIVE
  To observe the inhibitory effect of nimotuzumab combined with low-dose continuous irradiation using125I seeds on CAL-27 cells originating from human tongue squamous carcinoma, and explore the radiosensitization of nimotuzumab on human tongue squamous carcinoma CAL-27 irradiated with125I seeds.
  
  
  METHODS
  The exponential-phase CAL-27 cells were randomly divided into 4 groups: control group,125I seeds irradiation group, nimotuzumab group, nimotuzumab plus125I seeds irradiation group. CCK-8 assay was used to detect the inhibitory effect of125I seeds irradiation on CAL-27 cancer cells, and flow cytometry assays were performed to calculate the apoptosis rate of cells and cell cycle from each group. The morphology of cells was compared using Hoechst 33258 staining. The data were analyzed with SPSS17.0 software package.
  
  
  RESULTS
  125I seeds inhibited the growth of CAL-27 cells in time-dose dependent manner. The apoptosis rate of cells irradiated by nimotuzumab combined with125I seeds irradiation was higher than that treated with nimotuzumab and125I seeds irradiation respectively, and nimotuzumab followed by radiation had a lower S phase cells(P<0.05).
  
  
  CONCLUSIONS
  Nimotuzumab combined with125I seeds irradiation killed CAL-27 cells by inducing apoptosis. Nimotuzumab and low-dose γ ray emitted from 125I seeds can significantly enhance the radiosensitivity of CAL-27.
authors.affiliation: Department of Stomatology, Central Hospital of Xuzhou City. Xuzhou 221009, Jiangsu Province, China. E-mail:1776519397@qq.com.
authors.forename: Xing
authors.initials: X
authors.lastname: Wang
authors.forename: Jian-Min
authors.initials: JM
authors.lastname: Gu
authors.forename: Jian
authors.initials: J
authors.lastname: Meng
authors.forename: Cui-Ling
authors.initials: CL
authors.lastname: Shao
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D017209:Apoptosis; D002453:Cell Cycle; D045744:Cell Line, Tumor; D005434:Flow Cytometry; D006801:Humans; D011836:Radiation Tolerance; D011838:Radiation-Sensitizing Agents
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D011838:Radiation-Sensitizing Agents; C501466:nimotuzumab